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Abstract 
Dynamin 2 (DMN2) mutations cause centronuclear myopathy (CNM) and Charcot Marie Tooth 
(CMT). Herein we discuss the details of a patient's case of adult onset CNM. We also highlight 
the unique features of this case with regard to the importance of electromyography (EMG), 
muscle biopsy and genetic testing in identifying CNM, as well as potential for improving 




Centronuclear myopathy, dynamin 2, DNM2, muscular dystrophy, weakness 
Case Report 
A 67-year-old Caucasian male was referred to us for progressive diffuse muscle weakness after 
an inconclusive work up done out of state three years prior. He was born full term without 
complications, and his parents were not consanguineous. He reported that he kept up with his 
peers but avoided sports; he preferred books. At age 42 he noticed inability to tiptoe. At 57 he 
had difficulty climbing stairs due to foot drop and had trouble arising from chairs. He worked at 
a call center despite hand weakness and obtained disability benefits citing depression. By age 62 
he lost the ability to run. Family history included father with progressive foot weakness and loss 
of bulk in the lower extremities. Mother had heart failure. His paternal grandfather had a non-
specific “gait problem”. This patient was not married, did not have any children, and had no 
awareness of any siblings with the same symptoms.  
Neurologic exam  
Patient had normal cognition. Quadriceps and foot dorsiflexors were atrophic. We noted 
presence of a left pectoral crease, mildly arched palate, nasal speech, but no scapular winging, 
pyramidal signs, ophthalmoparesis, ptosis, dysphagia, scoliosis, or Beevor’s sign. Moderately 
severe muscle weakness was seen in distal and proximal upper and lower extremities. There was 
no neck or facial weakness, grip or percussion myotonia. Strength testing showed full (MRC 
grade) strength in pectoralis and ankle plantar flexion muscles, but only 4+ power in the deltoids, 
biceps brachii, triceps brachii and wrist flexors, along with 4 power in finger flexors and ankle 
dorsiflexors, and 4- power in quadriceps. No fasciculations were noted. Tendon reflexes were 
1+. Gait was significant for right foot drop.  
Laboratory testing  
Historically: ANA and antibodies to amphiphysin, CRMP5, calcium channels, acetylcholine 
receptor and voltage-gated potassium channels were negative.  
Other labs revealed: CK 53, serum myoglobin 55, TSH 1.46, ESR 26, vitamin D 31.2; negative 
LDH and MUSK ab.  
Imaging  
MRI scans were obtained using a GE 1.5T machine. MRI of lumbar spine showed severe right 
neuroforaminal narrowing at L4-5 but no canal stenosis. EKG revealed sinus bradycardia (HR 
56) with possible left atrial enlargement.  
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Historically, he had a normal repetitive nerve study. EMG was performed using standard routine 
technique on a Viking EDX EMG machine (2010 Carefusion Corporation, 20.1.32). Nerve 
conduction studies (NCS) of the right side of the body were normal. Needle EMG study of most 
muscles tested including cervical, thoracic and lumbar paraspinals showed small units, with short 
duration and early recruitment pattern indicative of a diffusely myopathic process. Fibrillations 
and positive sharp waves were seen in the right first dorsal interosseous, abductor policis brevis, 
lumbar and thoracic paraspinals. Waning discharges (pseudomyotonia) were detected in a right 
triceps brachii and semitendinosus muscles.  
Muscle biopsy 
Skeletal muscle was analyzed at University of Colorado Hospital with standard routine staining 
protocols for light microscopy. The right quadriceps showed marked variation in fiber size on the 
modified trichrome and H&E stains. (Figure 1) There were centrally placed nuclei in 70% of 
fibers. There was no necrosis, inflammation or phagocytosis. There was no increased connective 
tissue or endomysial fat on VVG stain. NADH-TR stain revealed mild coarsening of the 
intermyofibrillary network. ATPase series (pH 9.4 and 4.6) revealed a normal distribution of 
fiber types without type grouping but did show type 1 fiber hypotrophy. The non-specific 
esterase and acid phosphatase reactions were normal. PAS, Oil Red 0, and cytochrome oxidase 
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Figure 1. Muscle biopsy of a quadriceps muscle showing large central nuclei in fibers (black 
arrows) and type 1 fiber hypotrophy with increased space between muscle fibers (blue arrow) 






Marshall Journal of Medicine, Vol. 4 [2018], Iss. 4, Art. 4
https://mds.marshall.edu/mjm/vol4/iss4/4
DOI: http://dx.doi.org/10.18590/mjm.2018.vol4.iss4.4
Genetic testing  
Informed verbal consent was obtained prior to extraction of DNA from blood using an Invitae kit 
according to manufacturer’s instructions. The Comprehensive Neuromuscular Disorders Panel 
and Comprehensive Neuropathies Panel was negative for CMT and spinal muscular atrophy. A 
heterozygous pathogenic variant was found: c.1105C>T (p.R369W). Parental genetic data was 
unavailable.  
Discussion  
CNM is a rare congenital disease, with heterogenic etiology varying in phenotype and muscle 
histopathology. This condition is characterized by muscle weakness and may present at any point 
during life. There are several different forms. MTM1 mutations cause infantile x-linked CNM 
known as myotubular myopathy which is the most severe form leading to hypotonia, respiratory 
issues, contractures, feeding difficulties and cardiomyopathy.1 MTM1 mutation also causes late 
onset CNM with typical necklace fibers created by basophilic deposits. DNM2 mutations cause 
autosomal dominant (AD) or sporadic CNM with centralized nuclei in muscle fibers, type 1 
hypotrophy and radial sarcoplasmic strands (RSS). (Figure 1) DNM2 mutations predominantly 
involve distal weakness but sometimes limb girdle, ptosis, and muscle hypertrophy too with 
milder progression in adolescents and adults.2 BIN1 or RYR1 mutations also cause CNM.  
In our case AD inheritance was suspected due to presence of male to male transmission. DNM2 
mutation on chromosome 19p13.2 is allelic for CMT and CNM (Figure 2). However, CMT was 
thought unlikely given no large fiber neuropathy found on NCS and preserved reflexes. EMG 
abnormalities led us to order a muscle biopsy, and the histopathology was diagnostic.  
 
Figure 2. Protein structure of DNM2 composed of five domains including an N-terminal GTPase 
domain, a middle domain, a pleckstrin homology domain, a GTPase effector domain, and a C-
terminal proline-rich domain.9 R369W resides in the middle domain resulting in an attenuated 




Our patient had normal cognition and no cardiac complaints, however cognitive delay was 
reported in a family with a DNM2 mutation by Tranchant et al.3 Another cohort of ten Italian 
patients showed no obvious cognitive impairment, and only one had cardiac involvement 
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(tachycardia).4 Gal et al. reported a case of a DNM2 mutation manifesting at age 30 with 
cognitive delay, severe cardiomyopathy, axonal neuropathy and distal weakness, however that 
patient also had several mitochondrial DNA deletions.5 DNM2 mutation may exert these effects 
by causing disrupted cellular organization due to its role in endocytosis, membrane trafficking 
and cell motility.6 
Encouraging data from animal experiments using DNM2 knockdown, with anti-sense 
oligonucleotide to DNM2, showed prevention of myotubular myopathy in Mtm1KO mouse 
model by extending the lifespan and restoring muscle force in a dose-dependent manner.7 
However, currently we can only offer supportive care with cardiac surveillance as management 
for DNM2. A right ankle-foot orthotic was prescribed to correct our patient’s foot drop, and an 
echo is pending. Muscle MRI is non-invasive and is becoming more popular in identifying 
patterns of muscle involvement; it could facilitate subspecialty referrals to avoid delay in 
diagnosis.8 
Difficulty accessing specialty clinic resources in underserved regions is mainly due to lack of 
transportation and access to subspecialists. EMG, muscle biopsy and genetic testing are 
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